Sensa Core Medical Instrumentation Pvt. Ltd.

Sensa Core Medical Instrumentation Pvt. Ltd. is an India-based company that specializes in developing advanced in vitro diagnostic products, particularly point-of-care testing devices that enhance healthcare delivery. Founded in 2006 and headquartered in Hyderabad, India, Sensa Core Medical Instrumentation Pvt.

Ltd. focuses on creating innovative diagnostic solutions. The company has raised a total of USD 72. 00 mn in funding, with its most recent investment of USD 72.

00 mn secured in December 2025 from Motilal Oswal Private Equity Advisors. It has completed one funding round to date, positioning itself for significant growth in the healthcare diagnostics market. Sensa Core specializes in the development and manufacturing of advanced in vitro diagnostic (IVD) products, focusing on point-of-care testing (POCT) devices. Its core offerings include the ST 200 aQua Electrolyte Analyzer, which provides 27 test results from a single sample, and the Gluco Spark glucometer, known for delivering accurate glucose readings in five seconds.

Additionally, the Lacto Spark handheld lactate analyzer requires only 0. 5 µl of blood for rapid results. These products cater primarily to small and medium-sized laboratories and healthcare facilities across various international markets, including Asia, the Middle East, and Europe. Sensa Core generates revenue through direct sales of its diagnostic devices to healthcare providers, laboratories, and medical institutions.

The company primarily operates on a B2B transaction structure, forging partnerships with hospitals and clinics to supply essential testing devices such as the Gluco Spark and ST 200 aQua. Orders are generally made in bulk, ensuring a steady supply for routine diagnostic testing, with pricing reflecting the advanced technology utilized in their products, ensuring affordability and accessibility to their target market. In December 2025, Sensa Core Medical Instrumentation Pvt. Ltd.

raised USD 72. 00 mn in venture funding from new investor Motilal Oswal Alternates. The company plans to utilize this funding to enhance its manufacturing capacity, bolster research and development efforts, and support its growth strategy in both domestic and international markets. Specific targets for expansion into new geographic regions and the launch of new products are currently in development, aiming for timely releases to meet evolving healthcare demands.